Distinct signature type I interferon responses are determined by the infecting virus and the target cell.
BACKGROUND
Type I interferons (IFN) include multiple IFN-alpha subtypes which exhibit considerable amino acid identity and activate the same cell-surface receptor. The promoter regions of the IFN-alpha genes, however, have different transcription factor binding sites, implying differential transcriptional activation. Evolutionary conservation of multiple subtypes may have resulted from external pressures associated with the crucial nature of an IFN response, namely that different viruses that are tropic for different target tissues determine the nature and extent of an IFN response, specifically the IFN-alpha subtype profile.


METHODS
Studies were undertaken to examine inducible IFN gene expression profiles in response to infection with single-stranded RNA viruses: Sendai virus (SeV), murine hepatitis virus (MHV-1) and coxsackie virus B3 (CVB3).


RESULTS
In vitro, distinct signature profiles of SeV and MHV-1-inducible gene expression for IFN-alpha2, IFN-alpha4 and IFN-alpha5 subtypes in L2 and L929 mouse fibroblast cells, in relation to the extent and kinetics of their induction, were identified. In vivo, whereas A/J mice are highly permissive for both MHV-1 and CVB3 infections and mount a poor IFN response, C57B1/6 mice are relatively resistant to both virus infections and mount a vigorous IFN response.


CONCLUSIONS
These data suggest that the infecting virus and the target cell type dictate the extent and signature of inducible type I IFN gene expression. The extent of IFN response to viral infection influences the subsequent biological outcome: a robust IFN response prescribes a level of resistance, whereas a poor IFN response contributes towards a permissive phenotype for infection.
Division of Cell and Molecular Biology, Toronto General Research Institute, University Health Network & Department of Immunology, University of Toronto, Toronto, Canada.
Ehtesham
E
Baig
Eleanor N
EN
Fish
D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D017931:DNA Primers; D029822:Enterovirus B, Human / Q000472:pathogenicity*; D005260:Female; D005347:Fibroblasts / Q000276:immunology / Q000821:virology; D016898:Interferon-alpha / Q000235:genetics / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D008805:Mice, Inbred A; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D006517:Murine hepatitis virus / Q000472:pathogenicity*; D016133:Polymerase Chain Reaction / Q000379:methods; D011401:Promoter Regions, Genetic; D029082:Sendai virus / Q000472:pathogenicity*; D013045:Species Specificity
D017931:DNA Primers; D016898:Interferon-alpha